6657.TW Energenesis Biomedical Co. Ltd.
- Market cap
- TWD 2.60B
- P/E
- -
- P/B
- 3.65x
- ROE
- -51.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6657.TW undervalued?
Graham numberThe Graham number of Energenesis Biomedical Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Energenesis Biomedical Co. Ltd. fundamental analysis
No fundamental analysis for Energenesis Biomedical Co. Ltd. yet.
Energenesis Biomedical Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic …
Full company profileEnergenesis Biomedical Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Energenesis Biomedical Co. Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6.25M | 7.08M | 7.49M | 7.35M | 7.16M | 7.75M | 7.67M | 6.49M |
| Gross Profit | 3.87M | 4.83M | 5.36M | 5.17M | 5.23M | 5.69M | 5.83M | -7.45M |
| Operating Income | -149M | -129M | -120M | -265M | -262M | -255M | -275M | -384M |
| EBITDA | -131M | -109M | -97.1M | -241M | -238M | -208M | -253M | -372M |
| Net Income | -150M | -129M | -120M | -266M | -260M | -231M | -258M | -370M |
| EPS | -2.84 | -2.19 | -2.00 | -3.99 | -3.62 | -3.01 | -2.92 | -4.20 |
| Balance Sheet | ||||||||
| Total Assets | 814M | 705M | 886M | 631M | 829M | 781M | 949M | 784M |
| Total Liabilities | 27.1M | 32.5M | 33.4M | 28.3M | 24.6M | 41.3M | 52.7M | 71.1M |
| Shareholders' Equity | 786M | 673M | 852M | 603M | 804M | 739M | 896M | 713M |
| Cash & Short-term Investments | 643M | 544M | 726M | 485M | 699M | 665M | 838M | 677M |
| Total Debt | 12.2M | 14.9M | 11.9M | 9.54M | 8.28M | 10.0M | 14.8M | 11.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -121M | -98.9M | -97.3M | -233M | -225M | -181M | -222M | -292M |
| Capital Expenditure | 1.94M | 4.63M | 8.90M | 6.59M | 844K | 754K | 2.31M | 1.63M |
| Free Cash Flow | -123M | -104M | -106M | -239M | -226M | -181M | -225M | -293M |
| Ratios | ||||||||
| ROE | -19.0% | -19.2% | -14.1% | -44.1% | -32.4% | -31.3% | -28.8% | -51.8% |
| ROA | -18.4% | -18.4% | -13.6% | -42.1% | -31.4% | -29.6% | -27.2% | -47.1% |
| Net Profit Margin | -2,396.0% | -1,828.5% | -1,605.5% | -3,614.0% | -3,637.6% | -2,982.1% | -3,367.2% | -5,698.8% |
| Debt to Equity | 0.02x | 0.02x | 0.01x | 0.02x | 0.01x | 0.01x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Energenesis Biomedical Co. Ltd. dividends
Energenesis Biomedical Co. Ltd. has not paid dividends in the last 7 fiscal years.
Who owns Energenesis Biomedical Co. Ltd.
- Insiders 24.18%
- Institutions 0.02%
- Public & others 75.81%
- Shares outstanding 87.9M
- Free float 66.5M
Energenesis Biomedical Co. Ltd. company profile
- Company name
- Energenesis Biomedical Co. Ltd.
- Ticker
- 6657.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.21, Ln.583, Ruiguang Road, Taipei, Taiwan, 11492
- Phone
- 886 2 2627 0835
- Website
- energenesis-biomedical.com
About Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, including western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.
Energenesis Biomedical Co. Ltd. management
7- Dr. Han-min ChenCo-Founder, CEO, Chairman & GM
- Mr. Jen-yi ChiuCo-Founder
- Ms. Pei-chao ChenHead of Accounting & Accounting Supervisor
- Dr. Lin JuncaiSenior Vice President & Head of R&D Center
- Mr. Ming-tsan ChiangVP, Corporate Governance Officer & Director of the General Administrative Division
- Chueh-Hua KuoChief Internal Auditor
- Mr. Chen JiafuDeputy General Manager & Head of Business Center